These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 10328304)

  • 61. Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt.
    Vogel GM; van Amsterdam RG; Kop WJ; Meuleman DG
    Thromb Haemost; 1993 Jan; 69(1):29-34. PubMed ID: 8446935
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Ability of high-affinity heparin fractions with decreasing affinity for antithrombin III to activate ATIII isoforms.
    Carlson TH; Kolman MR; Frees A; Babcock T
    Thromb Res; 1990 Aug; 59(3):521-30. PubMed ID: 2237824
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Heterogeneity of synthetic factor Xa inhibitors.
    Gerotziafas GT; Samama MM
    Curr Pharm Des; 2005; 11(30):3855-76. PubMed ID: 16305517
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Heparin-catalyzed inhibitor/protease reactions: kinetic evidence for a common mechanism of action of heparin.
    Griffith MJ
    Proc Natl Acad Sci U S A; 1983 Sep; 80(18):5460-4. PubMed ID: 6577437
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Inhibition of factor Xa-induced platelet aggregation by a selective thrombin inhibitor, argatroban.
    Kawai H; Yamamoto T; Hara H; Tamao Y
    Thromb Res; 1994 May; 74(3):185-91. PubMed ID: 8042187
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparative studies on the inhibitory spectrum of recombinant hirudin, DuP 714 and heparin on thrombin and factor Xa generation in biochemically defined systems.
    Kaiser B; Callas D; Hoppensteadt D; Mallinowska K; Fareed J
    Thromb Res; 1994 Mar; 73(5):327-35. PubMed ID: 8016817
    [TBL] [Abstract][Full Text] [Related]  

  • 67. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

  • 68. First steps in the direction of synthetic, allosteric, direct inhibitors of thrombin and factor Xa.
    Verghese J; Liang A; Sidhu PP; Hindle M; Zhou Q; Desai UR
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4126-9. PubMed ID: 19540113
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Chemistry and biology of heparin mimetics that bind to fibroblast growth factors.
    Hassan HH
    Mini Rev Med Chem; 2007 Dec; 7(12):1206-35. PubMed ID: 18220975
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Killing 2 proteinases with 1 (dual-acting) stone.
    Krishnaswamy S
    Blood; 2012 Mar; 119(10):2182-3. PubMed ID: 22403213
    [No Abstract]   [Full Text] [Related]  

  • 71. Chemical synthesis of heparin fragments and analogues.
    Petitou M; van Boeckel CA
    Fortschr Chem Org Naturst; 1992; 60():143-210. PubMed ID: 1483612
    [No Abstract]   [Full Text] [Related]  

  • 72. Switching mechanism from AR to EGFR signaling via 3-O-sulfated heparan sulfate in castration-resistant prostate cancer.
    Ota H; Sato H; Mizumoto S; Wakai K; Yoneda K; Yamamoto K; Nakanishi H; Ikeda JI; Sakamoto S; Ichikawa T; Yamada S; Takahashi S; Ikehara Y; Nishihara S
    Sci Rep; 2023 Jul; 13(1):11618. PubMed ID: 37463954
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Progress and challenges in the synthesis of sequence controlled polysaccharides.
    Fittolani G; Tyrikos-Ergas T; Vargová D; Chaube MA; Delbianco M
    Beilstein J Org Chem; 2021; 17():1981-2025. PubMed ID: 34386106
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Heparin binding preference and structures in the fibroblast growth factor family parallel their evolutionary diversification.
    Li Y; Sun C; Yates EA; Jiang C; Wilkinson MC; Fernig DG
    Open Biol; 2016 Mar; 6(3):. PubMed ID: 27030175
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Heparan sulfate separation, sequencing, and isomeric differentiation: ion mobility spectrometry reveals specific iduronic and glucuronic acid-containing hexasaccharides.
    Schenauer MR; Meissen JK; Seo Y; Ames JB; Leary JA
    Anal Chem; 2009 Dec; 81(24):10179-85. PubMed ID: 19925012
    [TBL] [Abstract][Full Text] [Related]  

  • 76. New synthetic heparin mimetics able to inhibit thrombin and factor Xa.
    Petitou M; Duchaussoy P; Driguez PA; Hérault JP; Lormeau JC; Herbert JM
    Bioorg Med Chem Lett; 1999 Apr; 9(8):1155-60. PubMed ID: 10328304
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Synthetic oligosaccharides having various functional domains: potent and potentially safe heparin mimetics.
    Petitou M; Driguez PA; Duchaussoy P; Hérault JP; Lormeau JC; Herbert JM
    Bioorg Med Chem Lett; 1999 Apr; 9(8):1161-6. PubMed ID: 10328305
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Assessment through chemical synthesis of the size of the heparin sequence involved in thrombin inhibition.
    Duchaussoy P; Jaurand G; Driguez PA; Lederman I; Ceccato ML; Gourvenec F; Strassel JM; Sizun P; Petitou M; Herbert JM
    Carbohydr Res; 1999 Apr; 317(1-4):85-99. PubMed ID: 10466208
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [New antithrombotic oligosaccharides].
    Petitou M; Hérault JP; Bernat A; Driguez PA; Duchaussoy P; Lormeau JC; Herbert JM
    Ann Pharm Fr; 1999 May; 57(3):232-9. PubMed ID: 10427858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.